Wang Y B, Shan N N, Chen O, Gao Y, Zou X, Wei D E, Wang C X, Zhang Y
Department of Paediatrics, Second Hospital, Shandong University, Jinan, China.
J Int Med Res. 2011;39(6):2201-8. doi: 10.1177/147323001103900616.
The balance between interleukin-18 (IL-18) and its endogenous antagonist, IL-18 binding protein (IL-18BP), was evaluated in children with Henoch-Schönlein purpura (HSP). Plasma IL-18 and IL-18BP levels and peripheral blood mononuclear cell IL-18 mRNA expression were significantly higher in patients with active HSP (n = 30) than in healthy controls (n = 20); IL-18BP mRNA expression was similar in active HSP and controls. Plasma levels and mRNA expression of IL-18 and IL-18BP in patients in remission (n = 19) were similar to those in controls. The ratios of IL-18 / IL-18BP plasma levels and IL-18 / IL-18BP mRNA levels in active HSP were significantly higher than in patients in remission and healthy controls. Thus, adequate IL-18BP to block the proinflammatory activity of IL-18 may not be present in active HSP and regulation of the IL-18 / IL-18BP balance might provide a potential therapeutic strategy.
在过敏性紫癜（HSP）患儿中评估了白细胞介素-18（IL-18）与其内源性拮抗剂IL-18结合蛋白（IL-18BP）之间的平衡。活动期HSP患者（n = 30）的血浆IL-18和IL-18BP水平以及外周血单个核细胞IL-18 mRNA表达显著高于健康对照（n = 20）；活动期HSP患者和对照的IL-18BP mRNA表达相似。缓解期患者（n = 19）的IL-18和IL-18BP血浆水平及mRNA表达与对照相似。活动期HSP患者的IL-18 / IL-18BP血浆水平比值和IL-18 / IL-18BP mRNA水平显著高于缓解期患者和健康对照。因此，活动期HSP可能不存在足够的IL-18BP来阻断IL-18的促炎活性，调节IL-18 / IL-18BP平衡可能提供一种潜在的治疗策略。
